Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• PFE shares have stabilized near recent highs around $27 amid oncology and obesity pipeline wins, including China approval for its GLP-1 drug and positive bladder cancer trial data.
• Q4 2025 revenues beat estimates at $17.6B despite COVID declines, with non-COVID growth at 9% operationally; 2026 guidance reaffirmed at $59.5-62.5B revenue.
• Analyst consensus holds at "Hold" with ~$28 average price target, supported by Argus upgrade to Buy citing GLP-1 and oncology progress.
• $29M SEC settlement win provides minor cash boost; stock trades at low forward P/E of ~9x with 6.5% dividend yield.
• Focus shifts to 20+ Phase 3 trials in 2026 for long-term growth in oncology, obesity, and vaccines.

Current Market Snapshot

PFE has shown resilience in recent trading sessions, hovering near the upper end of its 52-week range amid broader market volatility. Non-COVID product strength, particularly in oncology biosimilars, Prevnar, Eliquis, and Abrysvo, has offset declines in pandemic-related revenues, fostering a stable base. Investor sentiment reflects cautious optimism, balancing pipeline catalysts against patent pressures and macroeconomic headwinds in healthcare. Volume remains robust, signaling sustained interest from institutional holders drawn to the defensive profile and attractive yield.

Trending AI Robots

Tickeron's Trending AI Robots page showcases over 25 curated AI trading bots, selected by advanced AI analysis from hundreds available that trade thousands of tickers across diverse sectors. These top performers adapt to current market volatility, highlighting bots with standout stats like annualized returns up to +220%, win rates from 53% to 95%, and profit factors exceeding 25 in areas such as aerospace, energy, semiconductors, biotech, and volatility plays. Each bot employs unique strategies—trend following, dip buying, hedging—across timeframes like 5-minute, 15-minute, or 60-minute signals, trading 1-25 assets per agent. This variety empowers traders to match styles to risk profiles and conditions. Explore the page to identify bots suited to your approach and potentially enhance returns through automated, data-driven signals.

Recent Developments Driving PFE Price Action

Pfizer's stock has navigated a mix of pipeline triumphs and headwinds over recent weeks, stabilizing after initial dips from guidance concerns. Key catalysts include regulatory nods bolstering its oncology and obesity ambitions. China's National Medical Products Administration approved Pfizer's GLP-1 agonist ecnoglutide (Severwin) for chronic weight management, marking its first obesity drug entry into a massive market and intensifying competition with rivals like Novo Nordisk. This fueled optimism around the GLP-1 pipeline, enhanced by the $10B Metsera acquisition.

Oncology advances further supported sentiment: Phase 3 data showed PADCEV + Keytruda cut recurrence/death risk by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer, deepening growth prospects. The FDA granted full approval to BRAFTOVI + cetuximab for first-line BRAF V600E-mutant metastatic colorectal cancer. ViiV Healthcare (GSK/Pfizer JV) reported positive HIV data for long-acting therapies, including twice-yearly dosing potential.

Q4 2025 earnings on February 3 beat expectations with $17.6B revenue (down 1% YoY but +9% ex-COVID) and adjusted EPS of $0.66 vs. $0.57 consensus, alongside full-year 2025 revenue of $62.6B. Non-COVID operational growth hit 6% annually. However, reaffirmed 2026 guidance ($59.5-62.5B revenue, $2.80-3.00 adjusted EPS) below prior consensus tempered enthusiasm, reflecting COVID sales drop to $5B and initial LOE impacts. Shares dipped post-earnings but recovered.

Analyst moves mixed: Argus upgraded to Buy ($35 target) on GLP-1/oncology; RBC initiated Underperform on patent cliffs. A federal judge approved a $29M SEC settlement recovery tied to 2013 insider trading case, providing a small cash lift. CEO Bourla flagged FDA vaccine leadership concerns, amid broader regulatory noise. These developments linked to modest gains, with shares up ~3% over recent weeks despite sector pressures.

2026 Outlook and Key Factors to Monitor

As Pfizer enters 2026, attention centers on pipeline execution amid moderating COVID reliance and escalating LOEs ($1.5B impact, rising to $3B+ in 2027). The company anticipates 20+ pivotal Phase 3 starts, targeting oncology (e.g., PADCEV expansions, BRAFTOVI), obesity (Metsera assets like monthly injections), RSV (Abrysvo uptake), and next-gen vaccines including mRNA flu. Cost savings of $7.2B by year-end aim to offset pressures, supporting margins.

Investors should track obesity trial readouts, oncology approvals, and HIV long-acting progress for revenue diversification. Regulatory dynamics, including FDA interactions and China expansions, plus competitive positioning in GLP-1s and biosimilars, remain pivotal. Macro factors like U.S. pricing reforms and biosimilar erosion on Eliquis/Prevnar will test resilience. Strategic M&A and R&D allocation (~$10.5-11.5B) underscore focus on high-growth areas, positioning for post-2028 acceleration.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations